Medical Economics Expert Panel 12.2
News|Videos|February 11, 2025

Drug prices: Expensive, but for whom?

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

The Medicare Drug Price Negotiation Program selects drugs for price talks based on the highest level of gross covered costs to Medicare, not to beneficiaries. What does that mean? Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research, explains how costs add up for drugs that may be relatively inexpensive, but that are used by a large number of beneficiaries. That is a different calculation than drugs that cause sticker shock at the pharmacy counter.


Related to this article

Vincent Cantone: ©WellSpan Health
With projected shortfalls of 86,000 to more than 187,000 physicians within a decade, burnout, an aging workforce and capped residency slots are squeezing supply. Here are the training, payment, prior authorization and workplace changes that could help close the gap.
Qasim Faizan: ©WeBill Health
Starting Jan. 1, Medicare will pay 20% less for the lower-valued service when an office visit billed with modifier 25 falls on the same day as a zero-day global procedure. One claims report priced at local 2027 rates shows independent practices their exposure, and three documentation habits protect the visits that still qualify for full payment.